WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Singapore
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Yang Chu
Partner
Corporate
Hong Kong
yang.chu@wsgr.com

D852-3972-4986

Download vCard
Open PDF

Yang Chu is a corporate partner in the Hong Kong office of Wilson Sonsini Goodrich & Rosati. He has extensive experience advising clients on a broad range of corporate matters, including Hong Kong IPOs and follow-on equity and debt offerings, public and private M&A transactions and privatizations, and pre-IPO and cross-over financings. Yang also counsels Hong Kong-listed companies on post-listing compliance, corporate governance, executive compensation, and related regulatory matters.

Yang’s practice is focused on clients in the healthcare, life sciences, technology, media, consumer, and retail sectors, including corporates and their respective founders, executives, and private equity and venture capital investors.

Prior to joining the firm, Yang was a capital markets partner in the Hong Kong office of another international firm.

Yang is fluent in both Mandarin and English, and is conversational in Cantonese. 

Experience

Yang Chu is a corporate partner in the Hong Kong office of Wilson Sonsini Goodrich & Rosati. He has extensive experience advising clients on a broad range of corporate matters, including Hong Kong IPOs and follow-on equity and debt offerings, public and private M&A transactions and privatizations, and pre-IPO and cross-over financings. Yang also counsels Hong Kong-listed companies on post-listing compliance, corporate governance, executive compensation, and related regulatory matters.

Yang’s practice is focused on clients in the healthcare, life sciences, technology, media, consumer, and retail sectors, including corporates and their respective founders, executives, and private equity and venture capital investors.

Prior to joining the firm, Yang was a capital markets partner in the Hong Kong office of another international firm.

Yang is fluent in both Mandarin and English, and is conversational in Cantonese. 

Education
  • LL.B., London School of Economics and Political Science, 2006
Honors
  • Recognized in Chambers Global in the China: Capital Markets: Equity (International Firms) category, 2022-2026
  • Named a “Next Generation Partner” for Capital Markets (Equity), Hong Kong in Legal 500 Asia Pacific in 2023
  • Honored as a “Rising Star Partner” for Capital Markets: Equity, China in the IFLR1000 in 2023
  • Recognized as “Young Lawyer of the Year (Law Firm)” at the Asian Legal Business Hong Kong Law Awards in 2023
  • Named to “The A-List” by China Business Law Journal in 2021
Admissions
  • Solicitor, Hong Kong SAR
  • Solicitor, England and Wales
Credentials
Education
  • LL.B., London School of Economics and Political Science, 2006
Honors
  • Recognized in Chambers Global in the China: Capital Markets: Equity (International Firms) category, 2022-2026
  • Named a “Next Generation Partner” for Capital Markets (Equity), Hong Kong in Legal 500 Asia Pacific in 2023
  • Honored as a “Rising Star Partner” for Capital Markets: Equity, China in the IFLR1000 in 2023
  • Recognized as “Young Lawyer of the Year (Law Firm)” at the Asian Legal Business Hong Kong Law Awards in 2023
  • Named to “The A-List” by China Business Law Journal in 2021
Admissions
  • Solicitor, Hong Kong SAR
  • Solicitor, England and Wales
Focus Areas
  • Capital Markets
  • Corporate
  • Corporate Governance
  • Emerging Companies and Venture Capital
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
Recent Insights
Client Highlights
Wilson Sonsini Advises Frontage Holdings on Privatization and Asset Restructuring
On November 9, 2026, Frontage Holdings Corporation (Frontage) announced that it has entered into an agreement for (i) a privatization by way of scheme of arrangement through SanRex Limited, the offeror held by an investor consortium, and (ii) a subsequent asset restructuring (together, “the transaction”). Wilson Sonsini Goodrich & Rosati advised Frontage on the transaction.

Upon completion of the privatization, Frontage will become a wholly owned subsidiary of SanRex Limited. As part of the asset restructuring, Frontage’s business is expected to be divided among members of an investor consortium comprising Charles River Laboratories International, Inc. (expected to own and operate Frontage’s Exton, Pennsylvania-based bioanalysis and drug metabolism and pharmacokinetics (DMPK) business); a wholly owned subsidiary of Hangzhou Tigermed Consulting Co., Ltd., Frontage's controlling shareholder (expected to own and operate Frontage’s PRC-based business and the business currently owned and operated by Acme Bioscience, Inc. and/or its subsidiaries); and Dr. Song Li, chairman of Frontage's board of directors (expected to own and operate Frontage’s remaining business outside of the PRC). The transaction remains subject to shareholder and regulatory approvals.

Frontage is engaged in the provision of research, analytical, and development services throughout the product discovery and development continuum. Frontage provides integrated, scientifically driven support that enables biopharmaceutical and life science companies to achieve their product development goals.

The Wilson Sonsini team that advised Frontage on the transaction includes Yang Chu, Jie Zhu, Nicole Yuen, Yang Liao, Shuhan Zhang, Yuan Dong, and Yingqi Gu.

For more information, please refer to Frontage’s press release and the HKEX announcement.
Learn More
Client Highlights
Firm Advises Underwriters on Legend Biotech’s Public Offering
On June 17, 2026, Legend Biotech Corporation, a global leader in cell therapy, announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares of the company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, were approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. Wilson Sonsini Goodrich & Rosati advised the underwriters on the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Cookie Settings
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.